| KOMISJA NADZORU FINANSOWEGO | ||||||||||||
| Raport bieżący nr | 6 | / | 2020 | |||||||||
| Data sporządzenia: | 2020-02-12 | |||||||||||
| Skrócona nazwa emitenta | ||||||||||||
| MILESTONE MEDICAL | ||||||||||||
| Temat | ||||||||||||
| Receiving a Notice of Allowance for European Patent Related to Peripheral Nerve Block Instrument | ||||||||||||
| Podstawa prawna | ||||||||||||
| Art. 17 ust. 1 MAR - informacje poufne. | ||||||||||||
| Treść raportu: | ||||||||||||
| The Board of Directors of Milestone Medical Inc. (WAR: MMD, “the Company”, “the Issuer”), today announced that Milestone Scientific, Inc. (NYSE:MLSS), the licensor and the majority shareholder of the Issuer has received Notice of Allowance from the European Patent Office (EPO) covering its instrument for performing a peripheral nerve block (PNB). The CompuFlo® with Dynamic Pressure Sensing technology® is the only available device capable of precisely measuring, displaying, warning, controlling and recording needle tip pressure in real time to help reduce the risk of needle injury during PNB procedures, as recently stated by a world authority. The Board of Directors of the Company is pleased to announce this important Notice of Allowance from the European Patent Office covering its instrument for performing a peripheral nerve block. This patent award follows a similar patent in United States, and further expands the worldwide intellectual property. This instrument is designed to significantly improve safety, efficiency and efficacy of PNB procedures. The Board of Directors of the Company believes that PNBs represent an attractive market for the CompuFlo® technology, as PNBs are increasingly utilized in the treatment of trauma and surgical procedures, including orthopedic surgeries as well as for postoperative and nonsurgical analgesia. | ||||||||||||
| MESSAGE (ENGLISH VERSION) | |||
| MILESTONE MEDICAL INC | ||||||||||||||||
| (pełna nazwa emitenta) | ||||||||||||||||
| MILESTONE MEDICAL | ||||||||||||||||
| (skrócona nazwa emitenta) | (sektor wg. klasyfikacji GPW w W-wie) | |||||||||||||||
| NJ 07039 | . | |||||||||||||||
| (kod pocztowy) | (miejscowość) | |||||||||||||||
| South Orange Avenue Livingston | 220 | |||||||||||||||
| (ulica) | (numer) | |||||||||||||||
| +11 973 535 2717 | +11 973 535 2829 | |||||||||||||||
| (telefon) | (fax) | |||||||||||||||
| (e-mail) | (www) | |||||||||||||||
| 27-5484393 | ||||||||||||||||
| (NIP) | (REGON) | |||||||||||||||
| PODPISY OSÓB REPREZENTUJĄCYCH SPÓŁKĘ | |||||
| Data | Imię i Nazwisko | Stanowisko/Funkcja | Podpis | ||
| 2020-02-12 | Joseph D'Agostino | Chief Financial Officer | Joseph D'Agostino | ||
